# Cue Biopharma (CUE): Quarterly Results, a 79.9% Drop

> Source: IndicatorStack, https://indicatorstack.com/catalysts/cue-2026-11-17-earnings. Updated Nov 19, 2026, 4:31 AM ET. Prices are indicative. General market information, not a recommendation to buy or sell any security.

Cue Biopharma (CUE) announced third quarter 2026 financial results and recent business highlights at 4:48 PM ET on Monday, November 16, and the stock went from Monday’s $14.10 close to as low as $2.83. It finished the session −79.9% at $2.83 on 28.8 times its 20-day average volume. Here is how it traded, turn by turn, and how LiveChart’s stack read each one.

Catalyst Reaction by IndicatorStack, published Nov 19, 2026, 4:10 AM ET. NASDAQ: CUE, Biotechnology. All times ET.

## The numbers

- −79.9% Tuesday’s close ($14.10 to $2.83, low $2.83)
- 28.8× its 20-day average volume (4.2M shares on the day)
- 4:48 PM the catalyst crossed, ET (Monday, after the close)
- 5.8M float, shares (73% of the float traded on Tuesday)

## How the stack read it, checkpoint by checkpoint

| Checkpoint | When | Price | 5m stack bias | Compass |
| --- | --- | --- | --- | --- |
| Before | Mon close | $14.10 | Neutral | 15m and 1h down |
| Into the open | Tue 9:30 AM | $13.01 | Bearish, strong | 15m and 1h down |
| 30 minutes in | Tue 10:00 AM | $9.08 | Bearish, strong | 15m and 1h down |
| At the close | Tue 4:00 PM | $2.91 | Bearish, firm | 15m and 1h down |
| Wednesday’s close | Wed 4:00 PM | $4.73 | Bullish, firm | 15m and 1h still down |

## Timeline

### Monday, November 16

- 6:02 AM: Ownership stake over 5% (Schedule 13G) filed (Accepted by the SEC at 6:02:14 AM ET)
- 9:43 AM: Amended ownership stake (Schedule 13G/A) filed (Accepted by the SEC at 9:43:56 AM ET)
- 2:00 PM: Ownership stake over 5% (Schedule 13G) filed (Accepted by the SEC at 2:00:26 PM ET)
- 4:48 PM: Third quarter 2026 financial results and recent business highlights (Press release, GlobeNewsWire)
- 4:52 PM: Current report (Form 8-K) filed (Accepted by the SEC at 4:52:54 PM ET)

### Tuesday, November 17

- 4:00 AM: Premarket high $13.80 (−2.1% from the prior close)
- 9:30 AM: Opened at $13.02 (−7.7% from Monday’s $14.10 close)
- 9:55 AM: Tripwire flagged a trap at the lows (a push through support that failed to hold, at $9.08)
- 3:55 PM: Session low $2.83
- 4:00 PM: Closed at $2.83, −79.9% on the day (4.2M shares, 28.8× its 20-day average)

### Wednesday, November 18

- 7:15 AM: 5-minute stack bias turned bullish (at $3.34)
- 9:30 AM: Opened at $3.41 (+20.5% from Tuesday’s $2.83 close)
- 9:40 AM: Session low $3.27
- 9:40 AM: Trigger marked a short at $3.36 (Hypothetical, default settings: closed at $3.88 at 9:50 AM for −1.8R (stop))
- 3:55 PM: Session high $4.77
- 4:00 PM: Closed at $4.76, +68.2% on the day (13.2M shares, 37.8× its 20-day average)

## Before the catalyst (Monday, November 16)

Cue Biopharma closed Monday at $14.10. The 5-minute stack bias was neutral, its inputs disagreeing. Compass read “15m and 1h down” (15m ↘ 1h ↓ 2h ↓ 4h ↘ D ↓). Undertow: buyers lead, no large size yet. Tripwire: Shorts: Clean, nothing major in the way. Its Next row read “Range 14.01 to 14.58, no edge in the middle”.

Over the year before, it had traded between $4.97 and $45.50.

## The quarterly results and a 79.9% drop (Tuesday, November 17)

The release crossed at 4:48 PM ET on Monday. It opened at $13.02, −7.7%, and the regular session ranged from $2.83 to $13.52 before closing at $2.83. It did this on a day SPY fell 1.0% and XBI, the biotechnology ETF, fell 0.4%.

Into the open the stack read it as bearish (strong) with 2 of 2 higher timeframes down, and Undertow read “selling drying up”. Thirty minutes in, the picture had changed: price was below VWAP at $12.19 and the Next row read “Stretched below the averages, bounce area near 10.93”. By the close the 5-minute bias was bearish from 6:35 PM, while Compass still read “15m and 1h down”: the day’s trend on the 5-minute chart had turned while the higher timeframes it is measured against had not.

## The session after (Wednesday, November 18)

It opened at $3.41 (+20.5%) and traded from $3.27 to $4.77, closing at $4.76, +68.2% on 13.2M shares, still 37.8 times its 20-day average. The 5-minute stack bias was bullish (firm), since 7:15 AM: over VWAP 4.25 and a rising SMA, momentum up and trend strength with the buyers. Compass read “15m and 1h still down” (15m ↘ 1h ↘ 2h ↘ 4h ↘ D ↘). Undertow: buying drying up, price higher, flow lower. Tripwire: Longs: Clean, nothing major in the way.

After hours it last traded at $4.79, with Undertow reading “hidden buying”.

## Supply

|  |  |  |
| --- | --- | --- |
| Shares outstanding | 7.3M | as reported to the SEC |
| Float | 5.8M | 80% of shares outstanding |
| Reverse splits on record | 1 | 1-for-30 reverse split, April 24, 2026 |
| Last insider purchase | June 1, 2026 | 91K shares at $0.0010 by Lin Shao-Lee (director, officer: Chief Executive Officer) |
| Last insider sale | October 12, 2026 | 2K shares at $28.05 |

## Sources

- Mon Nov 16, 4:52 PM ET, SEC filing: Current report (Form 8-K) (SEC EDGAR) https://www.sec.gov/Archives/edgar/data/1645460/000119312526463741/cue-ex99_1.htm
- Mon Nov 16, 4:48 PM ET, Press release: Third quarter 2026 financial results and recent business highlights (GlobeNewsWire) https://www.globenewswire.com/news-release/2026/11/16/3404177/0/en/cue-biopharma-reports-third-quarter-2026-financial-results-and-recent-business-highlights.html
- Mon Nov 16, 2:00 PM ET, SEC filing: Ownership stake over 5% (Schedule 13G) (SEC EDGAR) https://www.sec.gov/Archives/edgar/data/1583977/000117266126005293/xslSCHEDULE_13G_X02/primary_doc.xml
- Mon Nov 16, 9:43 AM ET, SEC filing: Amended ownership stake (Schedule 13G/A) (SEC EDGAR) https://www.sec.gov/Archives/edgar/data/938206/000093820626000052/xslSCHEDULE_13G_X02/primary_doc.xml
- Mon Nov 16, 6:02 AM ET, SEC filing: Ownership stake over 5% (Schedule 13G) (SEC EDGAR) https://www.sec.gov/Archives/edgar/data/1218710/000117266126005042/xslSCHEDULE_13G_X02/primary_doc.xml
- Tue Nov 10, 4:58 PM ET, SEC filing: Amended ownership stake (Schedule 13G/A) (SEC EDGAR) https://www.sec.gov/Archives/edgar/data/1645460/000142050626002561/xslSCHEDULE_13G_X02/primary_doc.xml

## Questions

### Why did CUE stock go down on November 17?

Cue Biopharma (CUE) announced third quarter 2026 financial results and recent business highlights at 4:48 PM ET on Monday, November 16, and the stock went from Monday’s $14.10 close to as low as $2.83. It finished the session −79.9% at $2.83 on 28.8 times its 20-day average volume. The reaction describes the sequence and infers no cause.

### What did Cue Biopharma announce on November 16, 2026?

Cue Biopharma (CUE) announced third quarter 2026 financial results and recent business highlights at 4:48 PM ET on Monday, November 16.

### How did CUE stock trade on November 17?

CUE opened at $13.02, −7.7% from the prior close of $14.10, traded between $2.83 and $13.52 in the regular session and closed at $2.83, −79.9%, on 4.2M shares.

### How did LiveChart’s stack read CUE at the close on November 17?

At the 4:00 PM ET close the 5-minute stack bias on CUE was bearish (firm), Compass read “15m and 1h down” and Undertow read “selling drying up”. Each turn of the read is on this page’s timeline.

### What does LiveChart’s stack read on CUE now?

The read on this page is fixed at each moment it describes. LiveChart reads CUE on every bar as it trades: open it on LiveChart for the current stack bias, levels and every layer.

Chart: https://indicatorstack.com/chart/CUE. CUE catalyst history: https://indicatorstack.com/catalysts/stock/CUE

Each reaction describes what happened and when, infers no cause and takes no view on what comes next. Past reactions don’t predict future ones.

---

IndicatorStack: on-chart analysis for active traders. LiveChart (https://indicatorstack.com/chart) reads every bar of any US-listed ticker into one held stack bias, the levels to watch and Compass, free. Site guide: https://indicatorstack.com/llms.txt. Today's digest: https://indicatorstack.com/llms-full.txt. Risk Disclosure: https://indicatorstack.com/risk
